Is Microdosing Legal in Canada?
Generally no, microdosing is illegal under Canadian federal law unless one is (perhaps incorrectly) referring to microdosing cannabis.
Psychedelic microdosing is effectively illegal in Canada, as possession of the substances typically used for microdosing, like psilocybin and LSD, are criminally prohibited regardless of quantity.
On June 7th, 2024, following a court-mandated re-assessment, Health Canada granted a Special Access Program (SAP) application for psilocybin microdosing to treat cluster headaches (see Health Canada’s response letter here). This marked the first time anyone in Canada has been granted legal access to psilocybin for the purpose of microdosing or treating cluster headaches.
In November 2025, Health Canada issued a s. 56(1) class exemption allowing participants in authorized clinical trials to take home and self-administer psilocybin or MDMA, a change that makes microdosing trials, which require frequent small doses over extended periods, substantially easier to run in Canada.
What is Microdosing?
Microdosing is the practice of ingesting a minuscule amount of a psychedelic substance.
Done properly, microdosing is sub-hallucinogenic, meaning one shouldn’t really feel the consumed substance’s psychedelic effects. At least not much.
Microdosing has become extremely popular of late, though its scientific efficacy remains subject to debate.
Medical or Therapeutic Use?
Proponents claim the practice of microdosing yields various benefits, such as improved focus, mood, and creativity. Though conversely, some studies suggest the touted benefits of microdosing are just a placebo effect.
Frequently Asked Questions
-
Microdosing has the same legal status as the underlying substance. Microdosing psilocybin or LSD is illegal because those substances are prohibited under the Controlled Drugs and Substances Act, regardless of dose size. Legal microdosing is possible only within authorized pathways such as clinical trials or, in rare cases, Special Access Program approvals.
-
Yes, in authorized trials. In November 2025, Health Canada issued a s. 56(1) class exemption allowing participants enrolled in authorized clinical trials to take home and self-administer MDMA or psilocybin, a change that facilitates microdosing research.
Reviewed by Marc Z. Goldgrub, Founding Lawyer, Green Economy Law Professional Corporation (Law Society of Ontario; New York State Bar) · Last updated: 2026-08-06
Stay updated on the firm’s work and psychedelic law developments in Canada and elsewhere.